Kwality Pharmaceuticals
Kwality Pharmaceuticals (KPL) share price was ₹3,696.70 at the 28 Oct 2026 close; market capitalisation ₹3,836 Cr; P/E (TTM) 47.33; sector Healthcare. The share price rose 307.1% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue rose 45.7% year on year to ₹162.4 Cr and net profit was ₹26 Cr, against ₹12 Cr a year earlier (compared with Jun 2025). Promoters held 54.86% of Kwality Pharmaceuticals in Sep 2026, unchanged from Jun 2026. Its Tapetide Score is 62/100 (Good) as of 28 Oct 2026.
Key Fundamentals
MicrocapPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of 29 Oct 2026, 10:45 IST · EPS basis: Consolidated · TTM
Peer Comparison
Healthcare › Pharmaceuticals
| ₹1,768.20 | 35.08 | 4,24,250 Cr | 5.08 | 0.91% | 13.79% | 17.94% | 61,848 Cr | 12,117 Cr | |
| ₹9,670.00 | 87.77 | 2,56,708 Cr | 15.32 | 0.32% | 15.32% | 18.96% | 11,682 Cr | 2,925 Cr | |
| ₹4,609.00 | 72.35 | 1,75,312 Cr | 9.54 | 0.82% | 12.16% | 9.06% | 17,058 Cr | 2,156 Cr | |
| ₹2,187.60 | 108.08 | 1,18,199 Cr | 22.30 | 0.09% | 16.38% | 19.67% | 7,323 Cr | 1,090 Cr | |
| ₹1,181.00 | 26.28 | 1,17,805 Cr | 4.35 | 0.09% | 16.99% | 19.24% | 28,515 Cr | 4,593 Cr | |
| ₹1,339.00 | 34.68 | 1,11,764 Cr | 2.88 | 0.61% | 10.87% | 13.94% | 34,247 Cr | 3,184 Cr | |
| ₹1,364.90 | 32.70 | 1,10,265 Cr | 3.12 | 0.96% | 11.21% | 14.88% | 28,589 Cr | 3,356 Cr | |
| Kwality Pharmaceuticals (this company) | ₹3,625.30 | 46.41 | 3,762 Cr | 11.37 | 0.00% | 20.41% | 27.40% | 557 Cr | 81 Cr |
| Median 8 companies | ₹1,977.90 | 40.75 | 1,18,002 Cr | 7.31 | 0.47% | 14.56% | 18.45% | 22,787 Cr | 3,055 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company. 1 company is not shown because they are not listed on an exchange we cover.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Data confidence 100/100
Category scores
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
4- Company is expected to give good quarter
- Company has delivered good profit growth of 34.8% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 18.1%
- Company's median sales growth is 27.4% of last 10 years
Weaknesses
3- Stock is trading at 11.5 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has high debtors of 203 days.
Technical Indicators
Oscillators
Neutral
Overall
Bullish
Moving Averages
Bullish
Growth Rate
change over 1 year
change over 1 year
change over 1 year
change over 1 year Operating margin 25% · Jun 2026
AI Analysis — Bull vs Bear
Kwality Pharmaceuticals Ltd is a small-cap healthcare company with a market cap of ₹2,821 Cr, trading at a PE of 41.2x and 8.39x book value. The company has delivered strong profit growth of 35% CAGR over 5 years and ROE of 23% in the last year, but carries high debtor days of 203 and pays no dividend despite consistent profitability.
- Strong profit growth with 35% CAGR over 5 years and TTM profit growth accelerating to 71%
- Consistent ROE track record averaging 26% over 10 years, with 23% in the last year
- Robust sales growth of 26% CAGR over 3 years and 36% TTM, indicating sustained demand
- Median sales growth of 27.4% over last 10 years demonstrates long-term revenue consistency
- Stock price CAGR of 100% over 3 years and 72% over 5 years reflects strong market re-rating
- Company is expected to deliver a good upcoming quarter based on operational momentum
- Long-term compounded profit growth of 44% over 10 years shows durable earnings power
- High debtor days of 203 indicates significant working capital strain and potential collection risk
- PE ratio of 41.2x is expensive relative to the broader market and leaves little margin of safety
- Price-to-book of 8.39x is elevated, suggesting the stock prices in substantial future growth
- Zero dividend yield despite repeated profits suggests poor capital return to shareholders
- Stock has surged 128% in 1 year, raising the risk of mean reversion or correction
- Small market cap of ₹2,821 Cr implies lower liquidity and higher volatility risk
- Debt-to-equity ratio is not disclosed, creating uncertainty around the balance sheet leverage
- 52-week high and low data unavailable, limiting visibility into recent price range and support levels
This is AI-generated analysis, not financial advice. Do your own due diligence.
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 67 | 70 | 78 | 92 | 80 | 90 | 84 | 116 | 111 | 111 | 123 | 157 | 162 |
| Expenses | 54 | 54 | 61 | 71 | 63 | 70 | 67 | 90 | 87 | 86 | 93 | 118 | 121 |
| Operating Profit | 14 | 15 | 17 | 21 | 17 | 20 | 18 | 26 | 24 | 25 | 30 | 39 | 41 |
| OPM % | 20% | 22% | 21% | 22% | 22% | 22% | 21% | 22% | 22% | 23% | 24% | 25% | 25% |
| Other Income | 0 | 0 | 1 | -7 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 1 |
| Interest | 2 | 2 | 3 | 3 | 2 | 3 | 2 | 2 | 3 | 3 | 2 | 3 | 3 |
| Depreciation | 5 | 5 | 5 | 5 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| PBT | 7 | 8 | 10 | 6 | 11 | 13 | 11 | 19 | 17 | 18 | 22 | 32 | 34 |
| Tax % | 25% | 24% | 21% | 29% | 25% | 33% | 25% | 24% | 30% | 23% | 28% | 20% | 25% |
| Net Profit | 5 | 6 | 8 | 4 | 8 | 8 | 9 | 14 | 12 | 14 | 16 | 25 | 26 |
| EPS (₹) | 5.22 | 6.01 | 7.41 | 4.2 | 8.06 | 8.16 | 8.22 | 13.96 | 11.5 | 13.61 | 15.43 | 24.38 | 24.69 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 52 | 74 | 98 | 137 | 166 | 139 | 262 | 456 | 251 | 307 | 370 | 503 | 554 |
| Expenses | 49 | 69 | 89 | 126 | 150 | 125 | 233 | 285 | 190 | 241 | 290 | 385 | 419 |
| Operating Profit | 3 | 5 | 9 | 12 | 16 | 14 | 29 | 172 | 61 | 66 | 80 | 118 | 135 |
| OPM % | 6% | 7% | 9% | 8% | 9% | 10% | 11% | 38% | 24% | 22% | 22% | 24% | 24% |
| Other Income | 0 | 0 | 1 | 1 | 1 | 4 | 2 | 4 | -14 | -5 | 2 | 2 | 2 |
| Interest | 1 | 1 | 2 | 2 | 2 | 3 | 3 | 3 | 7 | 10 | 10 | 11 | 11 |
| Depreciation | 1 | 2 | 3 | 3 | 3 | 4 | 6 | 11 | 15 | 20 | 18 | 20 | 20 |
| PBT | 1 | 2 | 6 | 7 | 11 | 11 | 21 | 162 | 26 | 31 | 54 | 89 | 106 |
| Tax % | 41% | 48% | 42% | 39% | 31% | 25% | 30% | 26% | 25% | 24% | 26% | 25% | — |
| Net Profit | 1 | 1 | 3 | 4 | 8 | 8 | 15 | 120 | 19 | 24 | 40 | 67 | 81 |
| EPS (₹) | 0.92 | 1.55 | 3.23 | 4.39 | 7.28 | 8.02 | 14.6 | 116 | 18.67 | 22.94 | 38.41 | 64.91 | 78.11 |
| Div. Payout % | 0% | 0% | 9% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4 | 5 | 5 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves | 15 | 17 | 20 | 19 | 27 | 36 | 51 | 171 | 190 | 214 | 254 | 321 |
| Borrowings | 8 | 13 | 19 | 26 | 29 | 35 | 41 | 54 | 90 | 98 | 112 | 130 |
| Other Liabilities | 10 | 17 | 26 | 40 | 39 | 52 | 64 | 105 | 70 | 72 | 71 | 130 |
| Total Liabilities | 37 | 51 | 71 | 96 | 105 | 133 | 166 | 341 | 361 | 394 | 447 | 592 |
| Fixed Assets | 13 | 13 | 17 | 20 | 29 | 43 | 57 | 92 | 120 | 139 | 146 | 156 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 12 | 14 | 0 | 0 | 17 |
| Investments | 1 | 2 | 4 | 5 | 5 | 4 | 5 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 24 | 37 | 50 | 70 | 71 | 86 | 102 | 237 | 226 | 255 | 302 | 420 |
| Total Assets | 37 | 51 | 71 | 96 | 105 | 133 | 166 | 341 | 361 | 394 | 447 | 592 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 1 | -3 | 4 | -1 | 14 | 6 | 27 | 61 | 41 | 43 | 53 | 17 |
| Investing | -1 | -2 | -7 | -6 | -12 | -18 | -23 | -63 | -48 | -26 | -29 | -35 |
| Financing | 1 | 6 | 5 | 5 | -2 | 12 | 1 | 6 | 1 | -17 | -14 | 7 |
| Net Cash Flow | 1 | 0 | 2 | -1 | 0 | 0 | 4 | 3 | -6 | -1 | 10 | -11 |
| Free Cash Flow | 0 | -5 | -2 | -7 | 2 | -12 | 3 | 5 | -4 | 17 | 28 | -29 |
| CFO/OP | 51 | -30 | 76 | 21 | 108 | 62 | 115 | 59 | 78 | 67 | 85 | 32 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 63 | 89 | 84 | 98 | 84 | 79 | 50 | 55 | 104 | 136 | 152 | 203 |
| Inventory Days | 61 | 67 | 71 | 54 | 34 | 94 | 38 | 97 | 310 | 187 | 167 | 111 |
| Days Payable | 40 | 63 | 65 | 80 | 52 | 96 | 58 | 63 | 117 | 106 | 112 | 144 |
| Cash Conversion Cycle | 85 | 93 | 90 | 73 | 67 | 77 | 30 | 90 | 297 | 217 | 208 | 170 |
| Working Capital Days | 35 | 41 | 20 | 18 | 20 | 43 | 24 | 60 | 118 | 101 | 98 | 128 |
| ROCE % | 9% | 13% | 19% | 19% | 22% | 18% | 26% | 98% | 19% | 16% | 18% | 24% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Kwality Pharmaceuticals insights
65 extracted metrics + investor summaries across FY15–FY27.
Documents
Frequently Asked Questions about Kwality Pharmaceuticals
What does Kwality Pharmaceuticals Ltd do?
Where is Kwality Pharmaceuticals Ltd (KPL) listed?
Which sector does Kwality Pharmaceuticals Ltd belong to?
What is the market capitalisation of Kwality Pharmaceuticals Ltd?
What is the PE ratio of Kwality Pharmaceuticals Ltd?
What is the 52-week high and low of Kwality Pharmaceuticals Ltd?
What is the Return on Equity (ROE) of Kwality Pharmaceuticals Ltd?
Company Information
Incorporated in 1983, Kwality Pharma is in the business of manufacturing & trading in Pharmaceuticals & allied products[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/539997.md for Kwality Pharmaceuticals Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.